Fig. 1S
The 1 H NMR spectrum of compound 1.
Fig. 2S
The local enlarged 1 H NMR spectrum of compound 1.
Fig. 3S
The 13 C NMR spectrum of compound 1.
Fig. 4S
The DEPT 135 spectrum of compound 1.
Fig. 5S
The HSQC spectrum of compound 1.
Fig. 6S
The local enlarged HSQC spectrum of compound 1.
Fig. 7S
The HMBC spectrum of compound 1.
Fig. 8S
The NOESY spectrum of compound 1.
Fig. 9S
The ECD spectrum of compound 1.
Fig. 10S
The HRESIMS spectrum of compound 1.
Fig. 11S
The IR spectrum of compound 1.
Fig. 12S
The 1 H NMR spectrum of compound 2.
Fig. 13S
The 13 C NMR spectrum of compound 2.
Fig. 14S
The HSQC spectrum of compound 2.
Fig. 15S
The HMBC spectrum of compound 2.
Fig. 16S
The ECD spectrum of compound 2.
Fig. 17S
The HRESIMS spectrum of compound 2.
Fig. 18S
The IR spectrum of compound 2.
Fig. 19S
The 1 H NMR spectrum of compound 3.
Fig. 20S
The 13 C NMR spectrum of compound 3.
Fig. 21S
The HSQC spectrum of compound 3.
Fig. 22S
The HMBC spectrum of compound 3.
Fig. 23S
The NOESY spectrum of compound 3.
Fig. 24S
The ECD spectrum of compound 3.
Fig. 25S
The HRESIMS spectrum of compound 3.
Fig. 26S
Plausible biogenetic pathway proposed for compound 3.
Fig. 27S
The 1 H NMR spectrum of compound 4.
Fig. 28S
The 13 C NMR spectrum of compound 4.
Fig. 29S
The HSQC spectrum of compound 4.
Fig. 30S
The HMBC spectrum of compound 4.
Fig. 31S
The HRESIMS spectrum of compound 4.
Fig. 32S
The chiral separation chromatograph of compound 4. 
Fig. 33S
The ECD spectrum reported by Nomura.
Fig. 34S
The dose-response curves of compounds 1-12 and kojic acid for tyrosinase inhibitory effects.
